Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort.

Aged Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms / drug therapy Cohort Studies Databases, Factual Female Humans Neoplasms, Second Primary Receptor, ErbB-2 Retrospective Studies

Breast cancer Clinical trial Epidemiology Geriatric oncology

Journal

Breast cancer research and treatment

ISSN: 1573-7217

Titre abrégé: Breast Cancer Res Treat

Pays: Netherlands

ID NLM: 8111104

Informations de publication

Date de publication:
Feb 2022

Historique:

received: 15 06 2021

accepted: 20 11 2021

pubmed: 6 1 2022

medline: 15 2 2022

entrez: 5 1 2022

Statut: ppublish

Résumé

Older cancer patients are underrepresented in clinical trials. We aimed to evaluate the enrollment of older women aged 70 years old (yo) or over with metastatic breast cancer (MBC) in clinical trials. We used the national Epidemio-Strategy and Medical Economics MBC Data Platform, a French multi-center real-life database. We selected MBC women over 70yo, without central nervous system metastases, with at least one line of systemic treatment, between January 1st, 2008 and December 31st, 2016, and had no other cancer in the 5 years before MBC. The primary objective was to evaluate the proportion of patients enrolled in clinical trials according to their age. Secondary objective was to identify variables associated with enrollment in older ones. 5552 women were aged ≥ 70 (median 74yo; IQR 72-77). 14,611 were less than 70. Of the older ones, 239 (4%) were enrolled in a clinical trial during first line of treatment, compared with 1529 (10.5%) for younger ones. Multivariable analysis of variables predicting for enrollment during first line of treatment in older patients were younger age (OR 0.50 [95%CI 0.33-0.76] for the 80-85yo class; OR 0.17 [95%CI 0.06-0.39] for the 85yo and more class), good ECOG Performance Status (PS 0-1) (OR 0.15 [95%CI 0.08-0.27] for the PS 2-4 class), HER2 + disease (OR 1.78 [95%CI 1.27-2.48]), type of treatment (chemotherapy/targeted therapy/immunotherapy OR 5.01 [95%CI 3.13-8.18]), and period (OR 1.65 [95%CI 1.22-2.26] for 2012-2016, compared to 2008-2011). In this large database, few older MBC patients were enrolled in a trial compared with younger ones.

Identifiants

DOI: 10.1007/s10549-021-06467-2 PMID: 34984582

pubmed: 34984582

doi: 10.1007/s10549-021-06467-2

pii: 10.1007/s10549-021-06467-2

doi:

Substances chimiques

Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Clinical Trial Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

Pagination

577-587

Informations de copyright

Références

National Cancer Institute. Surveillance, Epidemiology, and End result Program. https://seer.cancer.gov/statfacts/html/breast.html . Accessed 10 September 2020.

Deluche E, Antoine A (2020) Bachelot T Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicenter ESME cohort 2008–2016. Eur J Cancer 129:60–70. https://doi.org/10.1016/j.ejca.2020.01.016

doi: 10.1016/j.ejca.2020.01.016 pubmed: 32135312

Backer SD, Grochow LB (1997) Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 13(1):169–183

doi: 10.1016/S0749-0690(18)30188-5

Yuen GJ (1990) Altered pharmacokinetics in the elderly. Clin Geriatr Med 6(2):257–267

doi: 10.1016/S0749-0690(18)30615-3

Clegg A, Young J,Iliffe, et al (2013) Frailty in elderly people. Lancet 381(9868):752–762. https://doi.org/10.1016/S0140-6736(12)62167-9

doi: 10.1016/S0140-6736(12)62167-9 pubmed: 23395245

Ludmir EB, Mainwaring W, Lin TA et al (2019) Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.2055

doi: 10.1001/jamaoncol.2019.2055 pubmed: 31393530 pmcid: 6902229

Trimble EL, Carter CL, Cain D et al (1994) Representation of older patients in cancer treatment trials. Cancer 74(7 Suppl):2208–2214

doi: 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#

Le Saux O, Falandry C, Gan HK et al (2016) Inclusion of elderly patients in oncology clinical trials. Ann Oncol 27:1799–1804

doi: 10.1093/annonc/mdw259

Canouï-Poitrine F, Lièvre A, Dayde F et al (2019) Inclusion of older patients with cancer in clinical trials: the sage prospective multicenter cohort survey. Oncologist. https://doi.org/10.1634/theoncologist.2019-0166

doi: 10.1634/theoncologist.2019-0166 pubmed: 31324663 pmcid: 6975930

Tack L, Lefebvre T, Lycke M et al (2020) Underrepresentation of vulnerable older patients with cancer in phase II and III oncology registration trials: A case-control study. J Geriatr Oncol 11:320–326

doi: 10.1016/j.jgo.2019.09.003

Lackman M, Vickers MM, Hsu T (2020) Physician-reported reasons for non-enrollment of older adults in cancer clinical trials. J Geriatr Oncol 11:31–36

doi: 10.1016/j.jgo.2019.01.019

Talarico L, Chen G, Pazdur R (2004) Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 22(22):4626–4631

doi: 10.1200/JCO.2004.02.175

Mariano C, Francl M, Pope J et al (2015) Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials. Clin Breast Cancer 15(1):73–79. https://doi.org/10.1016/j.clbc.2014.09.002

doi: 10.1016/j.clbc.2014.09.002 pubmed: 25445420

Wildiers H, Glas NA (2020) Anticancer drugs are not well tolerated in all older patients with cancer. Lancet Healthy Longev. 1(1):e43–e47

doi: 10.1016/S2666-7568(20)30001-5

Inclusion of Older Patients in Cancer Clinical Trials. Guidance for Industry. FDA. March 2020. https://www.fda.gov/media/135804/download . Accessed 09 February 2021.

EMA geriatric medicines strategy. EMA. February 2011. https://www.ema.europa.eu/en/documents/other/geriatric-medicines-strategy_en.pdf . Accessed 09 February 2021.

Extermann M, Brain E, Canin B et al (2021) Priorities for the global advancement of care for older adults with cancer: an update of the international society of geriatric oncology priorities initiative. Lancet Oncol 22:29–36

doi: 10.1016/S1470-2045(20)30473-3

Pérol D, Robain M, Arveux P et al (2019) The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME). BMJ Open 9(2):e023568

doi: 10.1136/bmjopen-2018-023568

Hamaker ME, Seynaeve C, Nortier JW et al (2013) Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicenter OMEGA study. Breast 22(4):556–559. https://doi.org/10.1016/j.breast.2012.12.010

doi: 10.1016/j.breast.2012.12.010 pubmed: 23305962

Sedrak MS, Mohile SG, Sun V et al (2020) Barriers to clinical trial enrollment of older adults with cancer: A qualitative study of the perceptions of community and academic oncologists. J Geriatr Oncol. 11(2):327–334

doi: 10.1016/j.jgo.2019.07.017

Lee JY, Lim SH, Lee MY et al (2016) The impacts of inclusion in clinical trials on outcomes among patients with metastatic breast cancer (MBC). PLoS ONE 11(2):e0149432. https://doi.org/10.1371/journal.pone.0149432

doi: 10.1371/journal.pone.0149432 pubmed: 26901062 pmcid: 4763476

Hurria A, Dale W, Mooney M et al (2014) Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol 32(24):2587–2594. https://doi.org/10.1200/JCO.2013.55.0418

doi: 10.1200/JCO.2013.55.0418 pubmed: 25071116 pmcid: 4129504

Sedrak MS, Freedman RA, Cohen HJ et al (2021) Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA Cancer J Clin 71(1):78–92. https://doi.org/10.3322/caac.21638

doi: 10.3322/caac.21638 pubmed: 33002206 pmcid: 33002206